Inhibikase Therapeutics, Inc.
IKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3 |
| % Growth | -100% | 111% | -96% | – |
| Cost of Goods Sold | $0 | $14 | $0 | $11 |
| Gross Profit | -$0 | -$13 | $0 | -$8 |
| % Margin | – | -5,127.8% | 94.6% | -266.4% |
| R&D Expenses | $17 | $14 | $12 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11 | $7 | $6 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$14 | $0 | -$5 |
| Operating Expenses | $29 | $7 | $18 | $7 |
| Operating Income | -$29 | -$20 | -$18 | -$15 |
| % Margin | – | -7,712% | -14,686.2% | -476.2% |
| Other Income/Exp. Net | $1 | $1 | $0 | -$0 |
| Pre-Tax Income | -$28 | -$19 | -$18 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$28 | -$19 | -$18 | -$15 |
| % Margin | – | -7,304.8% | -14,625.9% | -476.9% |
| EPS | -1.16 | -3.57 | -4.26 | -4.88 |
| % Growth | 67.5% | 16.2% | 12.7% | – |
| EPS Diluted | -1.16 | -3.57 | -4.26 | -4.88 |
| Weighted Avg Shares Out | 69 | 5 | 4 | 3 |
| Weighted Avg Shares Out Dil | 69 | 5 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $15 |
| EBITDA | -$27 | -$20 | -$18 | $0 |
| % Margin | – | -7,643.9% | -14,620.4% | 0% |